Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.…
Acurx Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
Acurx Pharmaceuticals (NASDAQ: ACXP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 1.040 USD on 20 November 2026, down 81.7% over 52 weeks. Its 52-week range is 0.9171 USD to 7.539 USD: the price is 86.2% below the high and 13.4% above the low.
Its market capitalisation is 6.30M USD.
Acurx Pharmaceuticals reports return on equity of -151.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 9.65M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 12 March 2027.